September 11, 2006 – Genentech announced an Avastin setback today. Before approving the drug as a first-line therapy for metastatic breast cancer, the FDA has requested additional safety and efficacy information, which will take almost a year to complete. At that point, the FDA will take 6 months to review the information before issuing a ruling for this indication. In the pivotal Phase III trial, Avastin doubled the progression-free survival time of patients over the placebo. More details...
